Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vitamin D, Cardiovascular Disease, and African Americans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01655810
Recruitment Status : Completed
First Posted : August 2, 2012
Last Update Posted : June 5, 2020
Sponsor:
Collaborator:
American Diabetes Association
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
African-Americans have higher rates of cardiovascular disease morbidity and mortality, as well as vitamin D deficiency. Multiple observational studies have demonstrated an increased risk of vitamin D deficiency in African Americans with type 2 diabetes and correlation between cardiovascular disease and vitamin D levels; however, there is a lack of interventional trials exploring this connection. The objective of this proposal is to address the hypothesis that treatment of vitamin D deficiency in African Americans with type 2 diabetes will improve subclinical markers of cardiovascular disease.

Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Type 2 Diabetes Mellitus Cardiovascular Disease Dietary Supplement: Vitamin D3 Dietary Supplement: Calcium carbonate Not Applicable

Detailed Description:
This study will be a double blinded, randomized controlled trial of vitamin D3 supplementation, 4,000 international units per day versus 600 international units per day, for one year to determine the effects on markers of subclinical cardiovascular disease in African Americans with type 2 diabetes and vitamin D deficiency. Outcome assessment will focus on changes in carotid intima-medial thickness (CIMT - ultrasound of the thickness of blood vessels in the neck), as well as markers of systemic inflammation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vitamin D and Early Markers of Cardiovascular Disease in African Americans
Actual Study Start Date : August 13, 2012
Actual Primary Completion Date : February 9, 2018
Actual Study Completion Date : February 9, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Vitamin D 4000 IU
PO daily
Dietary Supplement: Vitamin D3
Multivitamin containing cholecalciferol 4000 units orally daily
Other Name: Cholecalciferol

Dietary Supplement: Calcium carbonate
500 mg orally twice daily

Active Comparator: Vitamin D 600 IU
PO daily
Dietary Supplement: Vitamin D3
Multivitamin containing cholecalciferol 600 units orally daily
Other Name: Cholecalciferol

Dietary Supplement: Calcium carbonate
500 mg orally twice daily




Primary Outcome Measures :
  1. Change from baseline in carotid intima-medial thickness [ Time Frame: 0, 6, and 12 months ]

Secondary Outcome Measures :
  1. Change from baseline in systemic inflammatory markers [ Time Frame: 0, 6, and 12 months ]
  2. Serum calcium [ Time Frame: 0, 1, 3, 6, 9, and 12 months ]
  3. Urinary Calcium [ Time Frame: 0, 1, 3, 6, 9, and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • African Americans of both genders
  • Age 50-70 years
  • Type 2 diabetes (A1C < 9.0%), on stable therapy with oral medications, insulin, or a combination
  • 25(OH)D level < 20 ng/ml
  • BP < 140/90 mmHg; LDL < 140 mg/dl

Exclusion Criteria:

  • Pregnancy
  • Cardiovascular disease
  • Stage 3 or worse chronic kidney disease
  • High urine or serum calcium or history of recurrent kidney stones
  • Unstable medical conditions or major systemic diseases such as malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655810


Locations
Layout table for location information
United States, Missouri
Washington University
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
American Diabetes Association
Investigators
Layout table for investigator information
Principal Investigator: Carlos Bernal-Mizrachi, MD Washington University School of Medicine
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT01655810    
Other Study ID Numbers: 201102160
First Posted: August 2, 2012    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Vitamin D Deficiency
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Calcium Carbonate
Micronutrients
Physiological Effects of Drugs
Calcium-Regulating Hormones and Agents
Bone Density Conservation Agents
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents